A Phase 1 Clinical Trial to Evaluate QTcF Prolongation and Proarrhythmic Potential of the Non Antiarrhythmic Drug Delgocitinib Following Oral Administration in Healthy Subjects
Latest Information Update: 14 Jan 2022
At a glance
- Drugs Delgocitinib (Primary)
- Indications Alopecia areata; Atopic dermatitis; Autoimmune disorders; Discoid lupus erythematosus; Eczema; Hypersensitivity; Inverse psoriasis
- Focus Adverse reactions
- Sponsors LEO Pharma
- 10 Jan 2022 Status changed from recruiting to completed.
- 13 Dec 2021 Planned End Date changed from 4 Dec 2021 to 4 Jan 2022.
- 13 Dec 2021 Planned primary completion date changed from 24 Nov 2021 to 20 Dec 2021.